HanAll's Partner HBM Initiates Phase 3 of Batoclimab in gMG in China
HanAll Biopharma (KRX: 009420.KS) today announced that its partner Harbour BioMed has commenced the first dosing of Phase 3 of batoclimab in patients with generalized myasthenia gravis (gMG) in China.
For more information, please refer to the link below.
- HBM press release link: https://www.harbourbiomed.com/news/167.html
NextHanAll's Partner HBM Completes First Dosing of Phase 2 of Batoclimab in TED in China
PrevHanAll's Partner HBM Announces IND Approval for Phase 2 of Batoclimab in CIDP in China